On May 2, 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) reported new results from 19 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting from 3rd – 7th June in Chicago, United States (Press release, Hoffmann-La Roche , MAY 2, 2016, View Source [SID:1234511800]). More than 200 abstracts have been accepted across eight cancer types, including four "late breakers" and nearly 30 oral presentations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The confluence of new medicines, sophisticated diagnostics and advanced technologies has created an unprecedented opportunity to improve outcomes for patients today and in the future," said Sandra Horning, M.D., Roche’s Chief Medical Officer and Head of Global Product Development. "At this year’s ASCO (Free ASCO Whitepaper) meeting, we look forward to presenting results from studies that have the potential to define new treatment approaches for cancers that have not seen significant progress in decades."

New trial results for atezolizumab include data from a study in which people received the medicine as an initial treatment for metastatic bladder cancer (first-line). These data will be highlighted as part of ASCO (Free ASCO Whitepaper)’s official press program. New overall survival and diagnostic results will be presented in recurrent metastatic bladder and lung cancer, and results from early combination studies of atezolizumab with targeted medicines and the investigational cancer immunotherapy MOXR0916, an OX40 agonist, will also be featured.

Roche will be presenting data from the J-ALEX trial, an open-label, randomised phase III study that compared Alecensa and crizotinib in people with ALK-positive advanced or recurrent NSCLC who had not previously received an ALK inhibitor and who had a maximum of one prior treatment with a chemotherapy.

Results for Roche’s haematology medicines include data from a study of MabThera/Rituxan in children with high risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL). Results from Phase I/II studies of Venclexta (venetoclax) in acute myeloid leukemia (AML), as well as the first data from a phase 1b study of Venclexta in B-cell NHL in combination with either MabThera/Rituxan and CHOP chemotherapy or Gazyva/Gazyvaro and CHOP chemotherapy, will also be presented. Venclexta is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche Group, in the United States and commercialised by AbbVie outside of the United States.

An analyst briefing to discuss key data presented on the Roche Group’s oncology products and pipeline at ASCO (Free ASCO Whitepaper) 2016 will take place on Sunday 5 June from 6:30 -8:00 pm CDT at the Marriott Downtown Chicago Magnificent Mile. This event, independently organized by Roche, is open to analysts and investors who have registered for the event. To register for the event, please follow the link (Password: Analyst2016)

Follow Roche on Twitter via @Roche and keep up to date with ASCO (Free ASCO Whitepaper) 2016 Annual Meeting news and updates by using the hashtag #ASCO16.

Overview of key presentations featuring Roche medicines at ASCO (Free ASCO Whitepaper) 2016

Medicine Abstract title Abstract number
Atezolizumab (investigational use) Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. Abstract LBA4500 (oral)
Sunday, 5 June
08:00-11:00 CDT

Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC). Abstract 4515 (oral)
Sunday, 5 June
08:00-11:00 CDT

Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). Abstract 9028 (poster)
Saturday, 4th June
08:00-11:30 CDT

Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab. Abstract 3005 (oral)
Saturday, 4 June
13:15-16:15 CDT

A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. Abstract 101 (oral)
Saturday, 4 June
08:00-09:30 CDT

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). Abstract 3502 (oral)
Sunday, 5 June
08:00-11:00 CDT

Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer (mTNBC) Abstract 1009 (poster discussion)
Sunday, 5 June
16:45-18:00 CDT

Alecensa (alectinib) (investigational use) Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from the J-ALEX study Abstract 9008 (oral)
Monday, 6 June
9:45-12:45 CDT

Avastin (bevacizumab) Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study Abstract 1013 (poster discussion)
Sunday, 5 June
16:45-18:00 CDT

ipatasertib (investigational use) Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study) Abstract 5017 (poster discussion)
Saturday, 4 June
13:00 – 16:30 CDT

MabThera / Rituxan (rituximab) (investigational use) Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high risk B-cell non Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen Abstract 10507 (oral)
Friday, 3 June
15:00-18:00 CDT

Venclexta (venetoclax) (investigational use) Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥65 years ineligible for standard induction therapy Abstract 7009 (poster discussion)
Monday, 6 June
11:30-12:45 CDT

Phase 1b/2 study of venetoclax with low-dose cytarabine in treatment-naïve patients aged ≥65 years with acute myelogenous leukemia Abstract 7007 (oral)
Saturday, 4 June
15:00-18:00 CDT

Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma Abstract 7566 (poster)
Monday, 6 June
8:00-11:30 CDT

About personalised cancer immunotherapy
The aim of personalised cancer immunotherapy (PCI) is to provide individual patients with treatment options that are tailored to their specific needs. Our PCI research and development programme comprises more than 20 investigational candidates, eight of which are in clinical trials. All studies include the prospective evaluation of biomarkers to determine which people may be appropriate candidates for our medicines. In the case of atezolizumab, PCI begins with the PD-L1 (programmed death ligand-1) IHC assay based on the SP142 antibody developed by Roche Tissue Diagnostics. The goal of PD-L1 as a biomarker is to identify those people most likely to experience clinical benefit with atezolizumab as a single agent versus those who may benefit more from combination approaches; the purpose is to inform treatment strategies which will give the greatest number of patients a chance for transformative benefit. The ability to combine atezolizumab with multiple chemotherapies may provide new treatment options to people across a broad range of tumours regardless of their level of PD-L1 expression.
Personalised Cancer Immunotherapy is an essential component of how Roche delivers on the broader commitment to personalised healthcare.